The University of Southampton
University of Southampton Institutional Repository

Antiviral treatment of severe non-influenza respiratory virus infection

Antiviral treatment of severe non-influenza respiratory virus infection
Antiviral treatment of severe non-influenza respiratory virus infection
PURPOSE OF REVIEW:

Non-influenza respiratory virus infections are a frequent cause of severe acute respiratory infections, especially in infants, the elderly, and the immunocompromised. We review here the current treatment options for non-influenza respiratory viruses and promising candidate antiviral agents currently in development.

RECENT FINDINGS:

Small molecule antiviral agents active against respiratory syncytial virus (RSV), such as ALS-8176 and GS-5806, show considerable promise in challenge studies and are undergoing late-phase clinical trials in hospitalised adults and children. Monoclonal antibodies (mAbs) active against non-influenza respiratory viruses are broadly at a preclinical stage. Broad-spectrum antivirals, such as favipiravir and nitrazoxanide, have potential utility in treating illness caused by non-influenza respiratory viruses but further definitive clinical trials are needed.

SUMMARY:

Severe non-influenza respiratory virus infection is common and current treatment is largely supportive. Ribavirin is used in immunocompromised patients but its use is limited by toxicity and the evidence for its efficacy is weak. Effective antiviral treatment for RSV may shortly become available, pending the results of ongoing clinical trials. For other non-influenza viruses, effective treatments may become available in the medium term. Early detection of respiratory viruses with rapid molecular test platforms will be crucial in differentiating virus types and directing the prompt initiation of novel treatments when available.
respiratory viruses, Antiviral Agents
0951-7375
573-578
Brendish, Nathan J.
d07b588f-4919-456d-8604-04efde7711fd
Clark, Tristan W.
712ec18e-613c-45df-a013-c8a22834e14f
Brendish, Nathan J.
d07b588f-4919-456d-8604-04efde7711fd
Clark, Tristan W.
712ec18e-613c-45df-a013-c8a22834e14f

Brendish, Nathan J. and Clark, Tristan W. (2017) Antiviral treatment of severe non-influenza respiratory virus infection. Current opinion in infectious diseases, 30 (6), 573-578. (doi:10.1097/QCO.0000000000000410).

Record type: Article

Abstract

PURPOSE OF REVIEW:

Non-influenza respiratory virus infections are a frequent cause of severe acute respiratory infections, especially in infants, the elderly, and the immunocompromised. We review here the current treatment options for non-influenza respiratory viruses and promising candidate antiviral agents currently in development.

RECENT FINDINGS:

Small molecule antiviral agents active against respiratory syncytial virus (RSV), such as ALS-8176 and GS-5806, show considerable promise in challenge studies and are undergoing late-phase clinical trials in hospitalised adults and children. Monoclonal antibodies (mAbs) active against non-influenza respiratory viruses are broadly at a preclinical stage. Broad-spectrum antivirals, such as favipiravir and nitrazoxanide, have potential utility in treating illness caused by non-influenza respiratory viruses but further definitive clinical trials are needed.

SUMMARY:

Severe non-influenza respiratory virus infection is common and current treatment is largely supportive. Ribavirin is used in immunocompromised patients but its use is limited by toxicity and the evidence for its efficacy is weak. Effective antiviral treatment for RSV may shortly become available, pending the results of ongoing clinical trials. For other non-influenza viruses, effective treatments may become available in the medium term. Early detection of respiratory viruses with rapid molecular test platforms will be crucial in differentiating virus types and directing the prompt initiation of novel treatments when available.

Text
COID Manuscript NJB.TWC.31.08.17. Final - Accepted Manuscript
Download (48kB)

More information

Accepted/In Press date: 17 November 2017
e-pub ahead of print date: 17 November 2017
Published date: December 2017
Keywords: respiratory viruses, Antiviral Agents

Identifiers

Local EPrints ID: 415733
URI: https://eprints.soton.ac.uk/id/eprint/415733
ISSN: 0951-7375
PURE UUID: 21c0cc24-6e41-4c43-935e-486c7c7bd1cd
ORCID for Nathan J. Brendish: ORCID iD orcid.org/0000-0002-9589-4937
ORCID for Tristan W. Clark: ORCID iD orcid.org/0000-0001-6026-5295

Catalogue record

Date deposited: 21 Nov 2017 17:30
Last modified: 15 Aug 2019 04:31

Export record

Altmetrics

Contributors

Author: Nathan J. Brendish ORCID iD

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×